Results 251 to 260 of about 1,322,570 (292)

Human Cyclophilins—An Emerging Class of Drug Targets

open access: yesMedicinal Research Reviews, EarlyView.
ABSTRACT Cyclophilins are a family of enzymes with peptidyl‐prolyl isomerase activity found in all cells of all organisms. To date, 17 cyclophilin isoforms have been identified in the human body, participating in diverse biological processes. Consequently, cyclophilins have emerged as promising targets for drug development to address a wide array of ...
Katarina Jurkova   +3 more
wiley   +1 more source

Investigating Tuberculosis Dynamics Under Various Control Strategies: A Comprehensive Analysis Using Real Statistical Data

open access: yesMathematical Methods in the Applied Sciences, EarlyView.
ABSTRACT In the present investigation, a mathematical model with vaccination, treatment, and environmental impact under real data is presented. Initially, we present the model without any interventions, followed by an examination of its equilibrium points.
Bashir Al‐Hdaibat   +4 more
wiley   +1 more source

Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 and Other Coronaviruses, December 2019 to July 2020 [PDF]

open access: gold
Kacie Grimm   +7 more
openalex   +1 more source

Coronaviruses remodel the mature human tRNAome to modulate infection. [PDF]

open access: yesVirulence
Wang Y   +5 more
europepmc   +1 more source

Increased Peritoneal Dialysis Associated Peritonitis Rate During Novel Coronavirus Pandemics [PDF]

open access: gold
Yelda Deligöz Bildacı   +7 more
openalex   +1 more source

Phase 3b Extension Study MT‐1186‐A04 to Evaluate the Continued Efficacy and Safety of Edaravone Oral Suspension for Up to an Additional 48 Weeks in Patients With Amyotrophic Lateral Sclerosis

open access: yesMuscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims An On/Off dosing regimen of intravenous (IV) edaravone and edaravone oral suspension is currently approved in the US for treatment of amyotrophic lateral sclerosis (ALS). Placebo‐controlled clinical trials showed that IV edaravone slows physical functional decline.
Angela Genge   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy